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The MDM familyproteins MDM2and MDMX are two critical regulators ofthe p53 tumorsuppressor protein. Expressionofboth
proteins is necessary for allowing the embryonal development by keeping the activity of p53 in check. Upon stresses that need to
activate p53 to perform its function asguardian ofthegenome,p53 hasto be liberated fromthese two inhibitors.In thisreview, we
will discuss the various mechanisms by which MDMX protein levels are downregulated upon various types of stress, including
posttranslational modiﬁcations of the MDMX protein and the regulation of mdmx mRNA expression, including alternative
splicing. In addition, the putative function(s) of the described MDMX splice variants, particularly in tumor development, will
be discussed. Lastly, in contrast to common belief, we have recently shown the existence of a p53-MDMX feedback loop, which is
important for dampening the p53-response at later phases after genotoxic stress.
1.Introduction
The tumor suppressor protein p53 is maintaining genome
integrity following stress signals by either inducing a cell
cycle arrest, allowing a complete checkup of the genome
beforeresumingDNAreplication,inducingsenescence,orby
stimulating apoptosis when the cell is beyond rescue [1]. In
addition, p53 has been shown to directly aﬀect DNA repair
by modulating expression of number of DNA repair genes
[2]. During tumor development, inhibition of angiogenesis
is part of the tumorsuppressor function of p53 [3]. In recent
years, it has been shown that p53 also aﬀects the metabolic
switch which occurs in many tumors, in which energy is
obtained by glycolysis rather than via oxidative phosphory-
lation [4]. p53 is activated by a plethora of stimuli, including
DNA damage, hypoxia, and oncogene activation, the ﬁnal
outcome of the activation being very dependent on the
strengthandtypeofthestimulusandthetypeoftargetedcell.
Whatever stimulus used to activate p53, it has become
clear that for full, but controlled p53 activation, a tight con-
trol of activity and levels of the main p53 inhibitors, MDM2
and MDMX, is necessary [8, 9]. Various mouse models
provide the best evidence regarding the importance of
MDM2andMDMXincontrollingp53activityundernormal
conditions.LossofeitherMDM2orMDMXexpressionleads
to embryonal lethality, which is rescued by simultaneous loss
of p53. Tissue-speciﬁc deletion of either the mdm2 gene or
the mdmx gene showed diﬀerences between cell types for
their dependency on MDM2 and MDMX to keep p53 in
check. These mouse models have recently been discussed in
two excellent reviews [9, 10].
The MDMX and MDM2 proteins have a similar struc-
tural organization (Figure 1).
MDM2 and MDMX bind via their N-terminal hydro-
phobic region to a short alpha-helical stretch within the
p53 N-terminus [11]; this N-terminal region is best con-
served between the two proteins. Other conserved structures
include the C-terminal RING ﬁnger domain, a Zn-ﬁnger
and a central acidic region. The RING ﬁnger domains of
MDMX and MDM2 are involved in their homo- and hetero-
multimerization [12]. MDM2 has convincingly been shown
to form both homo-oligomers and hetero-oligomers with
MDMX.Incontrast, nosigniﬁcant homo-oligomerizationof
MDMX could be found. This deﬁciency could have strong
implications for the function of MDMX (see below).
MDM2 is an E3 ubiquitin ligase that targets p53 for
ubiquitination and degradation. Essential for p53 ubiqui-
tination are both the MDM2 C-terminal region including2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of MDMX protein structure in comparison with MDM2. Most indicated protein modiﬁcation sites and
protein-protein interactions shown are discussed in the text. Modiﬁcations of MDMX by sumoylation (K254, K379) have not yet shown to
aﬀect function or regulation of MDMX [5]. Phosphorylation of S298 stimulates the associationof MDMX to p53 [6], and phosphorylation
of S96 has been reported to aﬀect the regulation of subcellular localization of MDM2 [7].
the RING ﬁnger and the acidic domain. Correspond-
ing regions of MDMX cannot fulﬁll this function [13,
14]. MDM2-mediated monoubiquitination of p53 leads to
nuclear export, thereby inhibiting the p53’s function as a
transcription activator. Moreover, it has become evident that
Mdm2- dependent mono-ubiquitination of p53 promotes
the localization of p53 to the mitochondria, where stress-
induced HAUSP-p53 complexes result in nonubiquitinated,
apoptotically active p53 [15]. Low levels of Mdm2 favor
mono-ubiquitination of p53, leading to this mitochon-
drialtranscription-independentinductionofapoptosisupon
stress. In contrast, high levels of Mdm2 and/or in combi-
nation with p300/CBP, promote polyubiquitination, which
results in proteasome-dependent degradation of p53 [16,
17]. As mentioned, MDMX has no detectable ubiquitin-
ligase itself, but has been proposed to inhibit p53 in a
dual way. First, MDMX binds tightly to the N-terminal
transcription activation domain of p53, in that way inhibit-
ing its function as transcription activator [18]. Binding of
MDMX to this part of p53 prevents the interaction of
p300, which results in reduced acetylation of p53 which is
involved in activation of p53 [19, 20]. Interestingly, p300
acetylates several lysines at the C-terminal region of p53 that
are also targeted by Mdm2-mediated ubiquitination [17].
This might implicate that MDMX indirectly stimulates the
MDM2-mediated ubiquitination by reducing the acetylation
of those lysines. It should be noted that the importance of
modiﬁcationsoftheC-terminal lysinesforcorrectregulation
of p53 stability and activity in vivo appears to be limited.
Krummel et al. [21] showed that a knock-in mutant mouse
in which the C-terminal lysines were replaced by arginines
developed normally. Several assays showed no diﬀerence in
regulation of wild-type p53 and p53-7KR. Only a minor
increased activation of p53 in the thymus upon ionizing
radiation was found, and, interestingly, p53-7KR MEFs
could not escape from senescence, in contrast to normal
MEFs, indicating an increased activity of p53-7KR. The
diﬃculty with interpretation of the results is that one cannot
distinguish between the functions of the various possible
modiﬁcations on the lysines (ubiquitination, sumoylation,
neddylation, methylation, and acetylation). It could well be
that a certain modiﬁcation on one lysine counteracts the
eﬀect of a diﬀerent modiﬁcation on a nearby lysine. In
Mdmx-deﬁcient MEFs, we have seen increased acetylation of
the one analyzed lysine in p53, K379. A full proteomic/mass
spec approach would be interesting to analyze the ratio
of various lysine modiﬁcations at the p53 C-terminus and
the eﬀect of diﬀerent MDMX expression levels on that
ratio.
What has become quite clearis that the ratio between the
levels of MDM2/MDMX strongly determines the outcome
on p53 stability. A relative high level of MDMX might
compete p53 away from MDM2, leading to p53 stabiliza-
tion [22]. In addition, as mentioned above, MDM2 and
MDMX interact via their respective C-terminal RING ﬁnger
domains, and it has been proposed that under nonstress
conditions, the MDM2/MDMX heterodimer functions as
am o r ea c t i v eu b i q u i t i nl i g a s ev i ap r o v i d i n ga ne x t e n d e d
interaction motif with the E2 protein [23–25]. One might
argue that only a dimer/oligomer of MDM2/MDMX RING
ﬁngers can bind the E2; since MDMX cannot homo-
dimeriz e,MDMXonitso wnisdefecti v easaubiquitinligase.
Thismight certainlybetrue,butisnotthewholeexplanation
since it has beenshown that just replacing the MDMX RING
with an MDM2 RING cannot rescue the ubiquitin-ligase
activity of MDMX [13, 14].
In this review, we will focus on the regulation of MDMX
expression upon various forms of stress. In most cases,Journal of Biomedicine and Biotechnology 3
a downregulation of MDMX protein is observed, which is
needed for full p53 activation. On the other hand, under
certain lethal conditions, a positive role for MDMX in
p53-induced apoptosis has been found. These various and
apparently contradictory results will be discussed. This
includes the recently discovered p53-MDMX feedback loop,
which aﬀects the outcome of genotoxic insults in cells.
2. MDMX RegulationuponGenotoxicStress
2.1. Inactivation of MDMX at the Protein Level. Interestingly,
initial reports indicated that MDMX levels were not aﬀected
by DNA damage or diﬀerentiation or during cell growth
[18, 26]. These wrong conclusions were caused by the
absence of high-aﬃnity antibodies and by our limited
insight into the ways MDMX mRNA levels were regulated.
The ﬁrst to notice that DNA damage inﬂuences MDMX
w e r eL ia n dc o w o r k e r s .T h e yo b s e r v e dt h a tD N Ad a m a g e
induces the nuclear translocation of exogenously expressed
MDMX, but an eﬀect on MDMX protein levels was not
discovered [27]. Although it had been reported that MDMX
could be degraded by a proteasome-dependent mechanism,
which isenhancedbyp53-andAdriamycin-inducedcaspase-
dependent cleavage of MDMX [28], only a year later it was
recognized that MDMX is a target of the ubiquitin-ligase
activity of MDM2 and that endogenous MDMX protein
is degraded upon DNA damage, in an MDM2-dependent
fashion [29–31]. Importantly, overexpression of MDMX
prevented p53 stabilization and activation [31]. Notably, in
thesestudies,noeﬀectonthetotalamountofMDMXmRNA
by ionizing radiation (10 Gy) was observed. Others and we
subsequently showed that the MDM2-mediated degradation
of MDMX is strongly stimulated upon ATM-dependent
phosphorylations on three serine residues, S342, S367, and
S403 [32–34]. These phosphorylations have multiple eﬀects,
including the temporal nuclear accumulation of MDMX in a
14-3-3-dependent manner [34–36].
Increased association of MDM2 with MDMX upon
phosphorylation of the latter has been suggested [32]a s
an explanation for the increased ubiquitination and degra-
dation of MDMX. Alternatively, we have shown that upon
ATM-dependent MDMX phosphorylation, the interaction
with the deubiquitinase HAUSP is strongly decreased and
that HAUSP interaction/expression is needed to maintain
endogenous MDMX levels [35, 37]. Whether the observed
increased interaction with 14-3-3 proteins and the decreased
interaction with HAUSP are causally related has not been
proven. Interestingly, recently the interaction motifs for
HAUSP on human MDMX have been mapped. It was found
that both an N-terminal motif (8AQCS11)a n dm o r eC -
terminal motif (398AHSS401)i nM D M Xc a ni n t e r a c tw i t h
HAUSP [38]. The latter is very close to the S403, which is
directly phosphorylated by ATM. Although not tested for
this particular motif, it was found that phosphorylation
of a serine residue two positions C-terminal of the core
motif could strongly inhibit the interaction with HAUSP
as assayed by peptide arrays. So, possibly both the direct
phosphorylation event on S403, and the interaction of
14-3-3 around phosphorylated S342 and S367 are involved
in decreasing the HAUSP/MDMX interaction.
Although one of the HAUSP interaction motifs in
MDM2 is also close to the phosphorylation targets Y394
and S395, these phosphorylation events do not appear to
aﬀectthe interaction with HAUSP[38]. EventhoughMDM2
lacks classic consensus sites for interaction, 14-3-3 proteins
have also been shown to bind MDM2. Two sites have
been mapped; one within the middle domain of MDM2,
dependent on phosphorylation by Pim1-kinase on S166 and
S186 [39]. However, this event appears to stabilize MDM2.
On the other hand, 14-3-3σ was shown to interact with
the RING ﬁnger domain of MDM2, in a phosphorylation-
dependent manner, and this interaction enhanced MDM2
ubiquitination and degradation [40]. Unfortunately, the
involved phosphorylation events (target sites, signaling cas-
cade)have not beeninvestigated, butthe 14-3-3σ interaction
domain was found rather far downstream of S395, which is
needed for the temporarily destabilization of MDM2 upon
ionizing radiation [41]; so, a causal relation is not obvious.
In addition, whether the observed eﬀects on MDM2 stability
are dependentonthisspeciﬁc isoformof14-3-3hasnot been
extensively investigated.
The above-reported regulation of MDMX protein lev-
els via ATM/Chk2 phosphorylations and 14-3-3/HAUSP
interactions were all upon treatment of cells with IR or
IR-mimetic NCS (neocarzinostatin). Surprisingly, UV-C
induced DNA damage also increases phosphorylation of
MDMX/Ser367 in a Chk1-dependent manner, but in this
case, the increased interaction with 14-3-3 results in cyto-
plasmic sequestering of MDMX [42]. This manner of
MDMX inactivation also turned out to be important for
a full p53-stabilization upon DNA damage. Unfortunately,
the authors did not investigate total levels of endogenous
MDMX after longer time-points after UV-C irradiation; it
is not excludedthat the observed change in localization, seen
three hours after UV-C, is a ﬁrst step in the inactivation of
theMDMXprotein,followedbyatotaldisappearanceoffull-
lengthMDMXproteineitherviaproteasomal degradation or
viaalternativesplicingoftheMDMXpre-mRNA(seebelow).
The physiological relevance of the UV-C mediated responses
is questionable, since humans are not exposed signiﬁcantly
to UV-C. The use of UV-A or UV-B irradiation would have
been better in that respect.
A recent elegant study with the use of a mouse knock-
in model has shown the importance of the S342, S367, and
S403 MDMX phosphorylations, not only for a DNA damage
response, but also in the regulation of tumor suppression
by p53 [43]. As could be extrapolated from the cell culture
studies, thymocytes or MEFs derived from the 3SA mutant
mice show decreased degradation of MDMX upon ionizing
radiation or neocarzinostatin treatment, and a concomitant
reduced p53 stabilization and activation. More striking is
the observation that crossing the 3SA mutant mice with
Eμ-Myc knock-in transgenic mice strongly decreased the
latency period for tumor formation. In the developing
tumors, no selection for p53 mutation was found in the
3SA mice, indicating that the expression of the mutant,
degradation resistant MDMX is suﬃcient to inhibit p53’s4 Journal of Biomedicine and Biotechnology
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Figure 2: Schematic representation of the MDMX protein, the mdmx mRNA and the reported mdmx splicing variants.
tumor suppressor function. Although the involvement of
other mechanisms cannot be excluded, it was found that the
overexpression of the Myc transgene did result in activation
of the double-strand DNA break DNA damage response,
which could explain the observation that prevention of DNA
damage-associated phosphorylations of MDMX impact on
the tumor development[43]. It should be noted that it is not
excludedthatother,yetundeﬁned,kinasesareinvolvedinthe
phosphorylation of MDMX which can be activated by Myc
overexpression.
In addition to the serine phosphorylations mentioned
above, also tyrosine phosphorylation of MDMX upon
imposing double-strand DNAbreakshas beenreported [44].
Tyrosine 55 and tyrosine 99 were identiﬁed as targets of
the c-Abl tyrosine kinase. Phosphorylations on these sites
increased upon DNA damage. Interestingly, Y99 phospho-
rylation was found to inhibit the p53/MDMX interaction,
which was supported by structural modeling. Function of
Y55 phosphorylation is not yet known, but appeared to be
dependent on Y99 phosphorylation, and the authors suggest
apossible role forY55 phosphorylation in therecovery phase
of p53 activation. These results indicate that double-strand
DNA breaks not only targets MDMX to activate p53 via the
ATM/Chk2 pathway to reduce MDMX levels, but also via
a very quick pathway, c-Abl mediated phosphorylation that
inhibits the MDMX/p53 interaction.
3.InactivationofMDMXatthe
PosttranscriptionalmRNA Level
Extensive alternative mRNA splicing of mdm2 has been
observed, especially in tumor cells [45]. In addition,
existence of some splicing variants of mdmx has also
been reported, mainly in tumors/tumor-derived cell lines
(reviewed recently by [46]). The so far identiﬁed mdmx
mRNA variants obtained by alternative splicing are depicted
in Figure 2. Chandler and colleagues investigated whether
genotoxic stresses would also aﬀect the splicing pattern
of mdm2 and mdmx [47]. It was observed that mdm2
showed alternative splicing upon treatment with rather
high doses of UV-C or cisplatin, but IR did not aﬀect
the splicing pattern. Similarly, mdmx alternative splicing
was observed upon 30 or 50J/m2 UV-C, but not with
10J/m2. Unfortunately, the eﬀect of cisplatin treatment on
mdmx mRNA splicing was not tested in this study. What
is missing from these studies is a clear quantiﬁcation of
the levels of the alternative spliced mRNAs compared to
the normal spliced mRNA. Even better would have been
to investigate whether the putatively produced alternative
protein products are indeed synthesized endogenously. For
MDMXthatmightbediﬃcult,becauseonlyfewhigh-quality
antibodies are available, but for MDM2 it could have been
performed. Possible functions of the protein products of
splicingvariantshavebeeninvestigatedalmost onlybystrong
overexpression, which might not reﬂect the physiologically
relevant situation. Therefore, no conclusions can be drawn
regarding a physiological function of the alternative splicing
after these high levels of DNA damage. The authors note
that they also detect low levels of another mdmx splicing
variant, mdmx-S [47]. This splicing variant, a result of exon
6 skipping, was ﬁrst described by Rallapalli and colleagues
[48]. The alternative splicing was mainly found in some
cancer cell lines and could be increased in nontransformed
cells upon serum-stimulation. The mdmx-S mRNA encodes
essentially only the p53 binding domain, and a number of
uniqueC-terminal amino acids (Figure 2). Inoverexpression
studies the MDMX-S product was found to be a stronger
inhibitor of p53 activity, most likely because this shortJournal of Biomedicine and Biotechnology 5
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Figure 3: The ratio between mdmx-S andmdmx-ﬂ mRNA is increased by various types ofDNA damageand by inhibition ofnuclear export.
RT-PCR analysis of RNAs extracted from various cell lines, treated for the indicated time periods with a variety of agents. The mdmx-
speciﬁc PCR primers are located in exon 3 and exon 8. The doses genotoxic/drug treatments used: UV-C: 15J/m2; cisplatin: 30μM; LMB
(Leptomycin B): 10nM; Eto (Etoposide): 20μM; Nutlin-3: 10μM.
proteinlocalized into the nucleusmuch more eﬃcientlythan
full-length MDMX [49].
Importantly, in recent experiments, we found that after
exposure of normal human ﬁbroblasts or MCF-7 cells to
relatively low levels of UV-C (10J/m2), splicing of mdmx
mRNAischanged,butthatpreferentiallythemdmx-Svariant
is expressed (Figure 3). This is a relative quick event in
the human skin ﬁbroblasts and occurs somewhat slower in
the MCF-7 cells. Under these conditions, the X-Alt1 and
X-Alt2 splice variants as described by Chandler et al. [47]
could not be detected. In addition, we found that cisplatin
(30μM) strongly induced the switch in ratio between full-
length mdmx- and mdmx-S mRNAs in the breast carcinoma
MPE600 cell line (Figure 3). Similar results were obtained
in other tumor cell lines, such as U2OS, upon treatment
with comparable concentrations cisplatin or with 20μM
doxorubicin(data not shown).
A tt h em o m e n ti ti sn o tk n o w nv i aw h i c hm e c h a n i s m
alternative splicing of mdmx is induced upon genotoxic
stress. From the literature, a few mechanisms can be
proposed. First, it has been shown that upon stress the
subcellular localization of proteins involved in splice site
selection is aﬀected, like the hSlu7 protein (3  site selection)
and the hnRNP A1 proteins (5  site selection). Treatment
of cells with osmotic shock or UV-C leads to cytoplasmic
localization of hnRNP A1, which aﬀects the choice of 5 
splice site [50]. Since with mdmx the change is the choice
of the 3  splice site, involvement of hSlu7 is more likely [51].
However, in that publication, it is mentioned that cisplatin
treatment does not aﬀect hSlu7 subcellular localization, so
regulation of hSlu7 is most likely not the single mechanism
by which the splicing of mdmx mRNA is altered. More
recently, it was reported that alternative splicing upon UV-
C treatment is coregulated with the inactivation of RNA
polymerase II by inducing the hypophosphorylation of the
CTD region [52]. Although such a mechanism cannot be
excluded at the moment in the alternative splicing of mdmx
mRNA, changes in subcellular localization of certain factors
involved in splicing are likely to play a role in the alternative
splicing of mdmx mRNA. We have found that the treatment
of several types of cells with Leptomycin B, which blocks
nuclear export of proteins containing a Rev-like nuclear
exportsignal,stronglyincreases alternativesplicingofmdmx,
leading to increased levels of mdmx-S mRNA and reduced
mdmx full-length mRNA (Figure 3), accompanied with a
reduced MDMX protein level (not shown).
Even so, it is unclear what the biological importance
of this alternative splicing is. It can be a means to reduce
the amount of full-length MDMX protein (which indeed is
found after sublethal doses of UV-C [31, 53]), needed for
full activation of p53. In this case, alternative splicing would
lead to a loss of function. On the other side, it could be
a mechanism to produce an MDMX protein form that is
resistant to MDM2-mediated degradation, which could have
a function in attenuating the p53 response at later time-
points after the damage. In that case, it would be a gain of
function.
Putative biological functions of protein products of the
mdmx splicing variants will be discussed later.
Markey and Berberich [54] have recently uncovered
another mechanism leading to reduction of MDMX protein
levels upon genotoxic agents. They found that exposing cells
to doxorubicin (0.5μg/mL; which is ∼0.85μM) leads to a
strong reduction in the total mdmx mRNA levels; this eﬀect
was found to be fully p53-independent. Similarly, cisplatin
reduces mdmx mRNA levels in doses varying from 25 to
100μM, on various cell lines, independent of their p53
status. In addition, the authors show that the decrease of
MDMX protein levels after doxorubicin treatment could not
eﬃciently be rescued by proteasome inhibition or knock-
down of p53 and MDM2, when measured 24hrs after start
of treatment. It would have been nice if the authors would6 Journal of Biomedicine and Biotechnology
have shown a time-course of doxorubicin treatment and
analyzed both MDMX protein and mRNA. It could well be
that initially degradation of the MDMX protein occurs upon
theactivation oftheDNAdamagesignalingcascade,andthat
the reduced mRNA level is a later eﬀect. These authors also
investigated the alternative splicing of mdmx mRNA upon
doxorubicin treatment. The remarkable observation here is
that for this experiment they use a 100μM concentration of
doxorubicin, which is more than 100-fold higher than used
in their initial experiment; so, it cannot be compared to the
earlier experiment. It could be, but that is not commented
upon, that at the lower concentration of doxorubicin no
signiﬁcant alternative splicing can be found. Anyway, the
authors do ﬁnd some increase in X-Alt2 levels, but actually a
small decrease in X-Alt1. Again, total levels of mdmx mRNA
strongly decrease, indicating that X-Alt2 only represents a
very small fraction of the total mdmx mRNA. Interestingly,
t h ed e c r e a s ei nmdmx mRNA levels is caused by decreased
stability of the mdmx mRNA. The authors suggest a putative
involvement of microRNA miR-34a in this regulation of
mdmx mRNA stability. This is interesting in the view of the
earlier observation that transcription of the miR34 family
membersisupregulateduponp53activation, which hasbeen
shown to be important for a full p53 response upon DNA
damage [55, 56]. However, the regulation of miR-34a by p53
does not explain the p53 independency of the mdmx mRNA
destabilization upon DNAdamage. Unfortunately, it was not
addressed inthisstudywhether thedecreaseinmdmxmRNA
after doxorubicin or cisplatin treatment is important for the
biological outcome of the treatment. So, the physiological
importance of the observed mdmx mRNA reduction still has
to be investigated.
4.AProapoptoticFunctionofMDMX upon
LethalDoses ofStress
In all the experiments presented above, the idea was that
a decrease in MDMX expression is needed to get a full-
blown p53-response upon DNA damage. And indeed, in
most cases, a decrease in MDMX levels is observed and some
experiments have shown that prevention of that MDMX
degradationisinhibiting thep53response [31,35].However,
these experiments were all done with a sublethal dose of IR
or treatment with IR-mimetic agents like NCS.
The group of Fabiola Moretti has obtained results that
appear to be in conﬂict with what has been discussed
above. In an initial report, it was presented that in an
(inducible) overexpression system high levels of MDMX
actually stimulate doxorubicin (adriamycin)-induced apop-
tosis [57]. This correlated with an increased induction of
Bax transcription, while p21WAF1 was induced similarly in
control- and MDMX-overexpressing cells, suggesting that
high MDMX expression facilitated p53-mediated induction
ofproapoptoticgenesspeciﬁcally.These experimentswereall
performed with theuse ofnontransformed mouse orhuman
cells, with doxorubicin as the genotoxic agent. The main
drawback of this study is that a pro-apoptotic function of
endogenous levels of MDMX protein was not investigated.
Furthermore,itcouldbethatMDMXhasadiﬀerentfunction
in untransformed versus tumor cells upon adriamycin-
treatment. In this respect, it is of interest to note that in
the colorectal tumor cell line HCT116 an active p53 seems
to inhibit adriamycin-induced apoptosis [58], so a pro- or
antiapoptoticfunction ofMDMXcouldverywell bestrongly
cell type speciﬁc.
In a follow-up study, the authors made the very intrigu-
ing observation that a fraction of MDMX is localized to
the mitochondria and that upon lethal stress MDMX could
function as an anchor for S46-phosphorylated p53, leading
to transcription-independent apoptosis [53]. Unfortunately,
the genotoxic agents used were now UV-C and cisplatin,
which makes comparison with the earlier publication dif-
ﬁcult. Strikingly, it was found that low levels of UV-C
irradiation did reduce MDMX protein levels in MCF-7 cells,
but that high, lethal doses (40J/m2)o fU V - Cd i dn o to r
much less. At these high doses, reduced levels of MDM2
were found, ﬁtting with earlier reports that lethal doses of
genotoxic agents can inhibit mdm2 transcription [59, 60],
partly by activation of HIPK2 [61, 62]. The results also lead
to two tentative conclusions. First, the observed alternative
splicing of mdmx mRNA after high UV-C doses in MCF-7
cells[47]would not leadto a reductionin full lengthMDMX
protein. Second, under these conditions the earlier reported
downregulationofmdmxmRNAlevelsupongenotoxicstress
[54], admittedly a diﬀerent type, is not occurring.
Most strikingly in this study is the observation that
reducing MDMX levels by siRNA did decrease the induc-
tion of apoptosis upon UV-C irradiation. A similar result
was obtained upon treatment of control- and MDMX-
knockdown MCF-7 cells with α-amanitin, which blocks
polymerase II transcription but is reported to induce a p53-
dependent apoptosis strictly by stimulating translocation of
p53 to the mitochondria.
Similarly, reducing MDMX levels in A2780 cells partly
prevents cisplatin-induced apoptosis (20μM cisplatin). This
concentration of cisplatin did not induce signiﬁcant alter-
native splicing of mdm2 mRNA in MCF-7 or U2OS cells
[47]. The eﬀects on mdmx mRNA were not investigated in
this study, but a similar dose of cisplatin (25μM) caused a
small upregulation of mdmx mRNA in MCF-7, but already
a downregulation in some other cell lines [54]. We found
recently in a few osteosarcoma cell lines that 20μM cisplatin
reduces the total levels of mdmx mRNA and increases the
mdmx-S: mdmx-FL ratio, independent of the p53 status
(Lenos et al., manuscript in preparation).
It is diﬃcult to reconcile the data from Moretti and
colleagues with the earlier presented data. However, there
are a number of points to keep in mind. The data obtained
with ionizing radiation orIR-mimetic usually didnot induce
a high level of apoptosis, but mainly a cell cycle arrest.
When UV-C was used, it was at relative low doses (5
or 10J/m2), which might give some apoptosis induction,
but not very high. The alternative splices as described by
Chandleretal.(2006)[47]wereonlyseenatratherhighdoses
of UV-C or cisplatin; these are in the same range as Moretti
and colleagues used, but Chandler et al. did not investigate
eﬀectsonproteinlevels.What canbenoticedfrom thatstudyJournal of Biomedicine and Biotechnology 7
is that while the dose of UV-C resulted in almost complete
alternative splicing of mdm2 mRNA (full length is hardly
detectableanymore), themainmdmxmRNAexpressedupon
treatment with 50J/m2 UV-C is still the ful-length mRNA.
So, it is possible that underthese ruthless conditions MDMX
protein is still expressed.
What we do ﬁnd somewhat surprising, though, is that
apparently the induction of apoptosis by 40J/m2 is largely
dependent upon the targeting of p53 into the mitochondria.
In several cellular systems, it has been reported that UV-
C (and cisplatin) can induce apoptosis in p53-null or p53-
mutantcells[52, 63–65],indicating thatwild-type p53status
is not a universal essential factor for UV-C or cisplatin-
induced apoptosis. It will be interesting to see whether
modulation of MDMX levels in p53-deﬁcient cells also
aﬀects the UV-C or cisplatin-induced apoptosis.
In an attempt to understand and reconcile the various
and sometimes contradicting results, a very well-structured
study should be performed in which one or two wild-
type p53 expressing cell lines, if possible with their p53-
deﬁcient counterparts, were treated with various types of
stress-inducing agents, mainly genotoxic agents like doxoru-
bicin, cisplatin, IR, and UV-C irradiation, but also with a
Polymerase-II transcription inhibitor like α-amanitin. Cells
should be extensively analyzed at early and late time-points
for expression of relevant genes (p53, MDM2, MDMX, p53-
targets) at protein and mRNA level (including analyses of
splicing variants) and for the biological outcome of the
treatment. The lattercanbedoneprimarily byFACSanalyses
to determine DNA proﬁle (PI staining), apoptosis (Annexin
V staining), and DNA replication (BrdU incorporation).
The importance of MDMX regulation can be determined
by using MDMX knockdown derivatives of the used cell
lines. Such a study should be able to provide the answers to
several questions regarding the regulation of MDMX by the
various agents, and the importance of that for the biological
response.
5.RoleofMDMX intheRibosomal
StressResponse:EssentialPartof
the DNA Damage Response?
In the last years, a strong link between nucleolar- and
ribosomal stress and p53 activation has been established.
Veryimportantly, RubbiandMilner showed thatdisturbance
of nucleolar integrity is important for the DNA damage
response [66]. As such, they already showed that the DNA
damage response and ribosomal stress are causally linked.
Several groups subsequently showed that upon nucleolar
disruption, ribosomal proteins are released, and several of
thoseinteractwithMDM2andpreventtheMDM2-mediated
degradation of p53 (recently reviewed by [67, 68]). Very
striking, none of the ribosomal proteins shown to interact
with MDM2 interact with MDMX, suggesting a selective
targeting by ribosomal proteins [69]. However, that does not
imply that MDMX is not important for the ribosomal stress
response. Indeed, these researchers show that upon treat-
ment of cells with Actinomycin D or 5-FU, at concentrations
that are reported not to induce a signiﬁcant DNA damage
response but only to give ribosomal stress, MDMX levels
are downregulated. Importantly, that downregulation is
needed for full p53 activation. The MDMX degradation
is MDM2-dependent, but is not associated with increased
phosphorylation of MDMX-Serine367, so is distinct from
the ATM/Chk2-stimulated MDMX degradation. Interest-
ingly, the treatment with these compounds leads to release
of L11 protein from the nucleoli, which binds MDM2 and
inhibitsMDM2-mediated degradationofp53,butstimulates
the MDMX ubiquitination by MDM2 [69]. MDMX over-
expressing cells showed an increased resistance to apoptosis
induction by 5-FU, and indeed MDMX also inhibited the
growth-suppressingeﬀectsof5-FUonxenograftsofHCT116
cells. Also in this case words of caution are needed. In the
model tested, the HCT116 cells, the 5-FU eﬀects are largely
dependent on wild-type p53 function, as shown earlier [58].
However, other studies indicate that the eﬀects of 5-FU on
colorectal tumor cells are only very limited dependent on
p53 status, and then only at really low concentrations [70].
Furthermore, in a small panel of 4 breast cancer cell lines,
all expressing wild-type p53 and sensitive to Nutlin-3, only
two showed a partial p53-dependence on growth inhibition
by 5-FU, while one cell line actually is sensitized for 5-FU by
reduced p53 levels [71]. The diﬀerential eﬀects can possibly
in part be explained by a diﬀerence in pRB status, which
seems to dictate the dependence of 5-FU responsiveness
on wild-type p53 status [72]. Therefore, it would be of
importance to investigate whether in other settings (e.g., p53
proﬁcient, but pRB-deﬁcient) MDMX levels also have an
impact on 5-FU sensitivity.
A recent study from the Prives’ lab showed another
cross-talk between ribosomal proteins and MDM2/MDMX
regulation of p53 [73]. They identiﬁed the small ribosomal
subunit protein S7 as an MDM2-interacting protein, which
can inhibit the MDM2-mediated degradation of p53. Inter-
estingly, they found that S7 could only perform its function
eﬃciently inthe presence ofMDMX. A putativeinvolvement
of S7 in MDM2-mediated degradation of MDMX was not
investigated. A striking observation of these investigators
was also that knockdown of either the ribosomal protein
L11 or S7 attenuated the p53 activation not only by agents
inducing ribosomal stress, but also DNA damaging agents
like doxorubicin and neocarzinostatin. These data conﬁrm
the earlier mentioned observations by Rubbi and Milner,
who already showed that DNA damage only aﬀects p53
stability when it is causing nucleolar disruption [66].
6.AlternativeSplicingofMDMX mRNA:
What Is Its Use?
At the moment, 6 diﬀerent splicing variants of MDMX have
beendescribed, which are schematically depictedinFigure 2.
As mentioned before, the ﬁrst reported splicing variant is
the mdmx-S mRNA, expression of which seemed to correlate
with transformed cells and with normal cells stimulated to
grow after serum-stimulation [48]. This was attributed to
the fact that MDMX-S protein, which essentially comprises8 Journal of Biomedicine and Biotechnology
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Figure 4: Expression of Mdmx-S protein is much lower compared to full-length Mdmx and increased upon MG132 treatment, whereas
mRNA levels are even higher in transfection studies. MCF7 cells were transfected with the indicated constructs (6-well plates; 1μgo fe a c h
construct/well; all well were also transfected with 250ng of CMV-eGFP expression vector as transfection control). Twenty four hrs after
transfection, the cells were either mock treated or treated with 20μM MG132 for 7 hours. Cell lysates were analyzed by Western Blotting
with the indicated antibodies (6658 = MDMX-S speciﬁc antibody) and extracted RNA was analyzed by quantitative real-time RT-PCR.
only the p53-binding domain (amino acids 1–114), and 26
uniqueC-terminal amino acids,i sas t r o n g e ri n h i b i t o ro fp 5 3
as assayed by overexpression studies [49]. What is important
to note is that the authors denote a protein of about 32kDa
in COS cells as the endogenous MDMX-S protein, which is
signiﬁcantly larger than the predicted molecular weight of
approximately 16kDa. The authors propose that this shift is
caused by post-translational modiﬁcation of the MDMX-S
protein, but the type of modiﬁcation was not determined.
Strikingly, in vitro translation of the mdmx-Sm R N Ay i e l d e d
also the 32kDa protein, and a protein of about 17kDa,
which could represent the “real” MDMX-S protein. We have
recently obtained evidence that the 32kDa protein is most
likely not representing the true MDMX-S protein.
Transfection of an MDMX-S expression vector, encom-
passing the total MDMX coding region but just lacking
exon 6, with an N-terminal HA-tag, results in expression
of a protein around 24kDa detected with anti-HA antibody
(Figure 4). Expression level of this protein is much lower
than that of full-length HA-MDMX protein upon trans-
fection of the same amount of plasmid DNA. In addition,
smaller proteins around 18kDa and 14kDa are found,
which are even lower expressed. However, we also made
an expression vector in which we truncated the mdmx
cDNA at an XbaI restriction site, just downstream of the
predicted stop codon of MDMX-S protein in exon 7. So,
this construct theoretically has the same coding potential.
When thisconstructisexpressed, onlythesmallerproteinsofJournal of Biomedicine and Biotechnology 9
about 18 and 14kDa can be detected with anti-HA, again at
low levelscompared to full-length HA-MDMX.Importantly,
an antibody raised against the C-terminal unique amino
acids of MDMX-S (Frank Bartel, personal communication)
recognizes only the 18kDa protein, identifying that as the
real MDMX-S protein. The anti-MDMX antibody MX-
82, with its epitope around amino acid 100 of MDMX,
recognizes both the 18kDa and 14kDa protein, but not
the 24kDa protein. Two conclusions can be drawn from
these results. First, the 24kDa protein, possibly reﬂecting
the 28kDa protein mentioned by Rallapalli et al. [48], is
most likely an artifact of the overexpression of the mdmx-S
cDNA, because it appears to lack the MX-82 epitope which
should be included in the MDMX-S protein. Secondly, the
smaller protein of about 14kDa lacks a C-terminal part
of MDMX-S; again most likely some artifact of the over-
expression. Importantly, when we use the same expression
plasmids for in vitro translation, we only detect the 18kDa
protein, either with an anti-MDMX antibody (1328; raised
against bacterially producedMDMX-S protein)or with anti-
MDMX-S speciﬁc antibody (Figure 4). In addition, His6-
tagged bacterially produced MDMX-S protein also has an
apparent molecular weight of about 18kDa.
Asmentioned,weﬁndthattheMDMX-Sproteinismuch
lower expressed compared to full-length MDMX, in contrast
to previous reports, but conﬁrming our previous ﬁnding
[20]. This is not a result of transfection eﬃciency, as can be
seen by the expression of the transfection control (Figure 4),
and similar results were obtained after transduction of
cells with lentiviral expression vectors for MDMX-S (not
shown). Furthermore, real-time Q-PCR analysis showed
that mdmx-S mRNA was even higher expressed than full-
length mdmx in these transfections (Figure 4(b)). Notably,
treatment oftransfected or transduced cells with proteasome
inhibitor MG132 strongly increased the MDMX-S protein
level, suggesting that the protein is very unstable. The levels
of full length MDMX protein are only mildly increased upon
MG132 treatment, while no eﬀect is seen on the 24kDa
protein. Although we have no evidence at the moment, the
rapid degradation of MDMX-S is possibly caused by the
unfolded protein response (UPR); it is possible that this
truncated MDMX protein is not properly folded,and as such
is targeted via UPR for degradation.
In addition, we have put much eﬀort in detecting the
endogenous MDMX-S protein, which we expected not to be
such a problem because the recently developed monoclonal
antibody, MX-82, has its epitope within the MDMX-S
region. However, even in cell lines that express more mdmx-
S mRNA compared to FL-mdmx mRNA, only full-length
MDMXproteincanbedetected(datanotshown). Therefore,
we propose that the induction of mdmx-S mRNA is a means
of reducing full-length MDMX levels, and not so much
the generation of a new MDMX Figure 3,w h e r ei tc a n
be seen that full-length mdmx mRNA decreases as mdmx-
S mRNA levels increase upon various stress conditions,
whereas MDMX-S protein levels are still undetectable (not
shown).
The MDMX-A and MDMX-G variants were cloned
from C33A cells, a somewhat exceptional cell line in that
it expresses high levels of mutant p53 but also high levels
of MDMX [30]. The corresponding MDMX proteins could
not unequivocally be identiﬁed, no biological function has
been determined, and whether this particular splicing event
is aﬀected by any event, like stress conditions, is unknown.
Therefore, these splicing variants will not be discussed here
any further.
As mentioned above, UV-C irradiation was found to lead
to alternative splicing of MDMX, resulting in X-Alt1 and
X-Alt2. Again, no functional studies have been performed,
synthesis of predicted alternative MDMX proteins has not
been investigated, and the ratio between the full-length
MDMX and the alternative splicing variants is not known.
Therefore, a biological relevance of these splicing variants is
still hypothetical.
Giglio and colleagues are the only group to report func-
tional experiments on an endogenously expressed MDMX
splice variant [74]. They identiﬁed an mdmx mRNA variant,
which they called mdmx211, in a thyroid tumor cell line
(ARO), which has structural similarity to the X-Alt2 variant
(see Figure 2). The protein products produced by these
variants bothlackthemajorpart ofthep53-bindingdomain,
but still contain the C-terminal domain including the RING
ﬁnger. A diﬀerence is that the X-Alt2 variant contains all
exon 11 encoded amino acids, including the Zn-ﬁnger, while
the mdmx211 variant lacks the N-terminal part of the exon
11. Overexpression experiments indicate that MDMX211
protein can stabilize MDM2 and prevents the degradation
of p53 by MDM2, reﬂecting what has been published
about full-length MDMX protein [75]. Overexpression of
MDMX211 increased colony formation of both p53-wt and
p53-negative cells, indicating a p53-independent oncogenic
role of MDMX211. Physiologically more relevant is the
speciﬁc knockdown of this MDMX variant in ARO cells.
Reducing levels of mdmx211 mRNA about 50% reduces
the viability of this cell line, suggesting that both full-
length MDMX and the alternative MDMX211 form are
contributing to the proliferation of these cells. However,
the eﬀects of speciﬁc knockdown of full-length MDMX
was not investigated in parallel, nor were relative levels of
MDMX and MDMX211 proteins compared. Knockdown
of MDMX211 did reduce MDM2 levels, but p53 levels or
activity was not investigated, probably because these cells
harbor a mutant p53. Again, these results are indicating a
p53-independent oncogenic function of MDMX211. It is
unfortunate that the authors have not studied the eﬀect of
speciﬁc knockdown of MDMX211 and full-length MDMX
in the FRO cell line, which appears to express similar levels
of MDMX211, but contains a wild-type p53 gene [76]. The
comparison between MDMX211 and FL-MDMX in this cell
line would especially have been interesting in the experiment
investigating the sensitivity to adriamycin treatment. As
mentioned earlier, Mancini and colleagues published that
overexpression of full length MDMX could increase the
sensitivity to adriamycin [57]; so, one would predict that
knockdown of MDMX would increase the number of viable
cells after adriamycin treatment. This would then indeed be
opposite from the eﬀects of knockdown of MDMX211 in
ARO cells, which increases the sensitivity to adriamycin in10 Journal of Biomedicine and Biotechnology
thesethyroid tumorcells[74]. Allinall, theseresultsindicate
that MDMX-211 has oncogenic potential, but whether that
is increased compared to full-length MDMX is not known at
the moment.
A number of studies investigated the expression levels
of mdmx mRNA and of mdmx splicing variants in a panel
of tumors. An analysis of malignant gliomas showed an
ampliﬁed mdmx gene in a subset of tumors, none of
which had p53mutation. Interestingly, ratio between mdmx-
S/mdmx-FL mRNA was found to be signiﬁcantly higher in
grade IV glioblastomas compared to grade III anaplastic
g l i o m a so rg r a d eI Ig l i o m a s[ 77]. Bartel and colleagues
studied 66 soft tissue sarcomas for mdmx gene ampliﬁcation
and mdmx-FL/mdmx-S mRNA expression [78]. They also
found an association between tumor grade and overexpres-
sion of the mdmx-S s p l i c ef o r m .F u r t h e r m o r e ,f r o mt h e i r
analyses they concluded that the mdmx-S is a prognostic
factor that predicts a poor outcome and a signiﬁcantly
shortened survival time for STS patients. No correlation
between p53 status and mdmx-S expression was evident.
Keepingin mind thatouranalyses so farsuggestthatincrease
in the ratio of mdmx-S mRNA compared to mdmx-FL
mRNA is more a means to decrease full-length mdmx, it
could imply a tumor suppressor function for the MDMX
protein, as is also suggested from the study of Moretti and
colleagues [79]. They found that in 57 papillary thyroid
tumors, which all contain a wild-type p53 gene, a decrease
of full length MDMX is associated with tumor stage (stage 1
versusothers), indicating downregulation ofMDMXprotein
levels during tumor progression. An increased ratio mdmx-
S:mdmx-FL (ratio ≥1.5) mRNA is found in a signiﬁcant
percentage of these thyroid tumors, but is not associated
with any clinical data. Expression of the mdmx211 mRNA is
also found in a subset of tumors, again not correlating with
any patient data. Together, these data on the expression of
mdmx-FL and mdmx mRNA splice variants in combination
with other analyses of mdmx gene ampliﬁcation, mdmx
mRNA expression and MDMX protein analyses in tumors
[80–83] strongly indicate that the function of MDMX in
tumorigenesis is strongly dependent on the tumor type.
Although in several tumor types MDMX appears to have an
oncogene function, in others it seems to be antioncogenic.
So far, the study by Moretti and colleagues has been the only
indicating a tumor suppressor role of MDMX in wild type
p53 expressing human tumors; unfortunately, the authors
do not show any data on the levels of p53 in these tumors.
Possibly, the p53 gene is still wild type but the expression
of the p53 mRNA is silenced yielding an essential p53-null
tumor. This is important in the light of other publications
in mouse models indicating an antiproliferative function of
MDMX[84,85].Intheﬁrst studyagrowthsuppressivefunc-
tion of mouse MDMX in a p21WAF1-deﬁcient background
wasobserved[84].Inaddition,inap53-nullbackgroundloss
ofMDMXincreased thegrowthofmouse embryoﬁbroblasts
and endogenous levels of MDMX suppresses tumorigenicity
in p53-null mice [85]. In p53-null cells, MDMX prevents the
chromosome loss in hyperploid cells by inhibiting spindle
multipolarity,inthatwaystimulatinggenomestability.Thus,
under certain conditions MDMX indeed can function as
an antioncogene. It would be interesting to investigate
whether the reduced MDMX expression in later stage
thyroid tumors [79] is correlated with low expression of
p21WAF1 and/or aneuploidy. Recently, two mouse models
have been published that overexpress an mdmx transgene.
Unfortunately, the mice show diﬀerent phenotypes, which
cannot easily be explained at the moment. In the ﬁrst model,
the generally overexpressed MDMX protein induces spon-
taneous tumor formation, mostly sarcomas, indicating an
oncogene function of MDMX [86]. MDMX overexpression
also strongly accelerated the tumor development of p53
heterozygousmice. Unfortunately,theeﬀectofMDMXover-
expression was not investigated in a p53-null background.
In the light of the study of Jones and colleagues [85],
showing that loss of MDMX in p53-null mice accelerates
tumor formation, one might predict that overexpression of
MDMX should reduce the rate of spontaneous tumor for-
mation in the p53-null mice. Surprisingly, the second mdmx
transgenic mouse model, in which a Myc-tagged MDMX is
overexpressed, does not accelerate tumor formation, neither
the spontaneous nor the Eμ-Myc induced tumorigenesis
[87]. Interestingly, only a heterozygous myc-mdmx trans-
genic mouse is viable; the homozygous transgenic mice die
during embryogenesis in a p53-independent manner, due to
massive vascular maturation defects. An in-depth side-by-
side comparison between the two mdmx transgenic mouse
models could possibly explain the observed diﬀerences in
phenotypes.
In conclusion, most available data suggest that the
human mdmx gene functions as an oncogene when overex-
pressed in tumors still expressing wild-type p53, which is
supported by most mouse models. However, the question
whether expression of MDMX or alternative MDMX pro-
teins produced by alternative splicing has an oncoprotein
or a tumor suppressor protein function in tumors lacking
p53 (or p21) or expressing a mutant p53 has still to be
answered.
7.TranscriptionalRegulationof
MDMX Expression
Uptill recently,itwas onlyGilkesandcolleagueswho investi-
gated regulation oftranscription initiation ofthe mdmxgene
[88].Theyfoundthat,likethemdm2P2promoter,mitogenic
signaling stimulates transcription of the mdmx promoter.
Especially two Ets-family binding sites are important in that
respect, and the MEK/ERK signaling pathway was found to
be involved in the induction of MDMX promoter activity
upon growth factor stimulation. Expression of oncogenic
K-Ras also activated the MDMX promoter. Importantly, in
a panel of colon tumors they ﬁnd an increasing MDMX
expression withtumorstage,and thisincreased expression of
MDMX does correlate to some extent with increased activity
of the MAPK pathway as measured by phospho-ERK stain-
ing. It is intriguing to note that around 50% of later stage
colon tumorsstain positive for MDMXin this study and that
approximately 50% of colon tumors contain p53 mutations.
It would have been interesting had the authors determinedJournal of Biomedicine and Biotechnology 11
the p53 status of the samples they used for MDMX staining
to investigate a putative-negative-correlation.
These results indicate that enhanced mitogenic signaling
in tumor cells which have lost p14ARF expression might
inhibit the tumor suppressor activity of p53 by enhancing
both mdmx and mdm2 gene transcription [88, 89].
More recently, a new twist to the p53/MDM2/MDMX
interactions has been added. Wei and colleagues had
reported that the intron 1 of the human mdmx gene contains
a p53RE, as identiﬁed in a global p53 ChIP experiment
[90]. Li et al. were the ﬁrst to publish that this p53RE
indeed mediates transcriptional activation of the mdmx gene
upon activation of p53 by Nutlin-3 [91]. Furthermore, they
provide evidence that reducing MDMX levels in the TGCT
(testicular germ cell tumor) cell line NT2/D1 induces low
levels of apoptosis, but strongly sensitizes these cells for
growth inhibition by Nutlin-3. However, this eﬀect was not
observed in other TGCT cell lines tested. The authors do
suggest that in the NT2/D1 cells MDMX is involved in a
negative feedback loop, similar to MDM2. These studies do
not distinguish between the importance of the constitutive
mdmx transcription and the p53-induced transcription. In
collaboration with the groups of Jeremy Blaydes and Frank
Bartel, we also recently reported that the previous identiﬁed
p53RE in the ﬁrst intron of mdmx is directing p53-induced
transcription of the mdmx gene [92]. In addition to the
earlier publication, we showed that the p53RE initiates
transcription from an alternative promoter (mdmx P2),
which includes an alternative ﬁrst exon (named exon 1β)i n
the mdmx mRNA. This exon contains an in-frame upstream
ATG relative to the canonical ﬁrst ATG, which results in the
synthesis of 18 extra-N-terminal amino acids. It was found
thatthemdmxP2 promotercanbe inducedin almost all cells
tested that express wild-type p53 (only a few primary human
cell cultures showed a very low or undetectable expres-
sion). Furthermore, every type of p53 activation (Nutlin-
3, DNA damage, ribosomal stress, Leptomycin B, activation
of p14ARF expression) increased transcription from the
mdmx P2 promoter. Most importantly, the inclusion in the
mdmx P2 mRNA of a unique exon provided us with the
opportunitytoinvestigate speciﬁcally the contributionofthe
p53-induced mdmx mRNA expression in the p53 response.
Indeed, shRNA targeting sequences in the unique exon 1β
increased the p53 response upon treatment of cells with
Nutlin-3orDNAdamage(etoposide)and enhancedthep53-
induced growth inhibition. These results together strongly
establish mdmx as a p53 target gene, involved in a negative
feedback loop to attenuate the p53 response.
8.Conclusionsand FuturePerspectives
When the identiﬁcation of the mdmx gene was presented
in 1996 [18], the p53 ﬁeld was not immediately impressed.
The added value of MDMX to MDM2 could not be
recognized. MDM2 was expected to be suﬃcient to keep
p53 in check and to regulate the p53 response. However,
the p53-dependent embryonal lethality of mdmx knockout
mice established MDMX as an essential regulator of p53
activity. In more recent years, it has become clearthat during
development MDM2 is the more general regulator of p53
activity. However, the intricate regulation of MDMX has
been shown to be essential for a controlled p53 response
upon various forms of stress, as much as MDM2 regulation.
Although great insight into regulation of MDMX expression
and activity has been obtained, much has still to be learned.
How is MDMX degraded upon ribosomal stress, since DNA-
damaged induced phosphorylations are not involved? How
is the alternative splicing of MDMX upon certain types of
genotoxic stress regulated? Do the various identiﬁed mdmx
mRNAsencodeproteinswith important biologicalfunctions
in the coordination of stress response or in tumorigenesis?
Underwhich circumstancesisMDMXactingasanoncogene,
and when is it stimulating the p53 tumor suppressor
response? The answers to these questions will be important
for understanding the role of MDMX in tumorigenesis, and
for obtaining more insight into the possibility to regard
MDMX as a target for therapeutic intervention in cancer.
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